A Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference

Simply Wall St.

昨天

Iovance Biotherapeutics (IOVA) recently outlined its growth plans at the Barclays 28th Annual Global Healthcare Conference, spotlighting early sarcoma data, broader lung and sarcoma ambitions, and ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2621719375"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621719375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621719375?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-22 14:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621719375","market":"hk","top_or_hot":-1,"title":"A Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference","media":"Simply Wall St.","content":"<div>\n<p>Iovance Biotherapeutics (IOVA) recently outlined its growth plans at the Barclays 28th Annual Global Healthcare Conference, spotlighting early sarcoma data, broader lung and sarcoma ambitions, and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/a-look-at-iovance-biotherapeutics-iova-valuation-after-pipel\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-22 14:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/a-look-at-iovance-biotherapeutics-iova-valuation-after-pipel><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Iovance Biotherapeutics (IOVA) recently outlined its growth plans at the Barclays 28th Annual Global Healthcare Conference, spotlighting early sarcoma data, broader lung and sarcoma ambitions, and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/a-look-at-iovance-biotherapeutics-iova-valuation-after-pipel\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/a-look-at-iovance-biotherapeutics-iova-valuation-after-pipel","article_id":"2621719375","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/a-look-at-iovance-biotherapeutics-iova-valuation-after-pipel","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621719375","pubTimestamp":1774159473,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Iovance Biotherapeutics (IOVA) recently outlined its growth plans at the Barclays 28th Annual Global Healthcare Conference, spotlighting early sarcoma data, broader lung and sarcoma ambitions, and upcoming Amtagvi melanoma regulatory decisions in the UK and Australia.\nSee our latest analysis for Iovance Biotherapeutics.\nAt a share price of $3.69, Iovance has given investors a 30 day share price return of 28.57% and a year to date share price return of 46.43%. However, the 5 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","IOVA":"Iovance Biotherapeutics, Inc.","XLV":"健康照护类股ETF-SPDR","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","BK4581":"高盛持仓","BK4139":"生物科技","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","XBI":"SPDR S&P Biotech ETF","LABU":"三倍做多标普生物-Direxion","BK4137":"综合支持服务","HCSG":"Healthcare Svcs Group Inc"},"translate_title":"巴克莱医疗保健会议上发布管道和监管更新后的Iovance Biotherapeutics(IOVA)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":0.6,"HCSG":1.5,"IOVA":1.5,"XBI":0.6,"XLV":1.5},"content_text":"Iovance Biotherapeutics (IOVA) recently outlined its growth plans at the Barclays 28th Annual Global Healthcare Conference, spotlighting early sarcoma data, broader lung and sarcoma ambitions, and upcoming Amtagvi melanoma regulatory decisions in the UK and Australia. See our latest analysis for Iovance Biotherapeutics. At a share price of $3.69, Iovance has given investors a 30 day share price return of 28.57% and a year to date share price return of 46.43%. However, the 5 year total shareholder return of 87.13% and 3 year total shareholder return of 33.27% indicate that recent momentum follows a much weaker longer term experience. If you are looking beyond a single biotech name, this can be a time to broaden your watchlist with other healthcare names using our screener for 35 healthcare AI stocks. With Iovance trading at $3.69 after a sharp 30 day rebound, yet still carrying a loss of $390.978 million and a value score of 4, is the current price an attractive valuation or has the market already accounted for these factors? AdvertisementMost Popular Narrative: 55.8% Undervalued Against a last close of $3.69, the most widely followed narrative assigns Iovance Biotherapeutics a fair value of $8.35, using a 7.15% discount rate to weigh future cash flows against today’s price.  Advancing multiple late-stage clinical programs for TIL therapies across solid tumor types (lung, endometrial, next-gen approaches) not only opens new addressable markets but also reduces reliance on Amtagvi alone, diversifying future revenue streams and stabilizing earnings outlook.  Read the complete narrative. Read the complete narrative. Curious what kind of revenue ramp and margin shift would need to sit behind an $8.35 fair value and a high implied earnings multiple? The core assumptions here lean heavily on rapid top line expansion, a swing into positive profitability, and a valuation multiple that usually belongs to faster growing sectors. The full narrative spells out how those pieces fit together and how sensitive that outcome is to even small changes in those inputs. Result: Fair Value of $8.35 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on key uncertainties, especially regulatory setbacks such as the withdrawn EMA filing for Amtagvi and the company’s heavy dependence on a single high priced therapy. Find out about the key risks to this Iovance Biotherapeutics narrative. Another Angle On The Price Tag The first narrative leans heavily on a discounted cash flow output of $8.35, which points to Iovance trading on a wide discount. Yet on a simple P/S lens, the picture is less clear. The current P/S is 5.8x versus a fair ratio of 4.2x and a US Biotechs average of 10.6x, so the stock screens cheaper than peers but richer than the level our models suggest the market could move toward. For investors, that tension raises a key question: is the DCF optimism or the revenue multiple caution closer to how you see the next few years playing out? For a revenue based view, it is worth checking how the current pricing stacks up against detailed ratio work in the full valuation breakdown. This walks through the gap between the present 5.8x P/S, the 4.2x fair ratio and the broader 10.6x sector context in more detail, See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:IOVA P/S Ratio as at Mar 2026Next Steps Given the mixed signals in this story, it can pay to review the numbers yourself and decide quickly where you stand on the balance of risks and rewards, starting with the 2 key rewards and 3 important warning signs. Ready to widen your opportunity set? If you stop with a single stock, you risk missing ideas that better fit your goals, time horizon, and comfort with risk.  Target potential mispricings by scanning a focused list of quality names that look cheap on the numbers using the 53 high quality undervalued stocks. Prioritise resilience by reviewing companies that pair robust finances with steadier risk profiles through the 68 resilient stocks with low risk scores. Get a head start on tomorrow’s potential leaders by working through a screener containing 26 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}